Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.12
+0.14 (1.56%)
At close: Mar 9, 2026, 4:00 PM EDT
10.75
+1.63 (17.87%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Zevra Therapeutics Revenue
In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth. Zevra Therapeutics had revenue of $34.13M in the quarter ending December 31, 2025, with 183.36% growth.
Revenue (ttm)
$106.47M
Revenue Growth
+350.91%
P/S Ratio
6.08
Revenue / Employee
$1,430,305
Employees
59
Market Cap
513.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Vanda Pharmaceuticals | 216.11M |
| Century Therapeutics | 113.34M |
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 75.21M |
| Prothena Corporation | 9.68M |
| Altimmune | 41.00K |
ZVRA News
- 5 hours ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call - GlobeNewsWire
- 12 days ago - Zevra Therapeutics to Present at the Citizens Life Sciences Conference - GlobeNewsWire
- 13 days ago - Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer - GlobeNewsWire
- 18 days ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 4 weeks ago - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewsWire